Skip to main content

Table 1 Summary of input parameters into health economic model

From: A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females

Input parameters Base Case Value References
Vaccination   
Efficacy HPV 16/18 98% (95% CI: 88.4-1000) [811]
Efficacy non-vaccine oncogenic HPV types 37% (95% CI: 7.4-58.0) [8, 9]
Duration of vaccine protection lifelong Assumption
Coverage rate 75% Assumption based on [50]
Screening   
Age and frequency Age 18-69, 70% (once/3 years), 12% (never) [39]
Cytology (Pap) test sensitivity 55.4% [57]
Cytology (Pap) test specificity 96.8% [57]
Costs and utilities   
Vaccination costs   
Vaccine per dose $135.00 Assumption
Screening Costs   
Conventional cytology $57 [7, 48]
Colposcopy + Biopsy $150 [7, 48]
Treatment Costs (annual)   
CIN 1 $782 [7, 48]
CIN 2/3 $1,353 [7, 48]
Cervical cancer stage 1 $11,915 [7, 48]
Cervical cancer stage 2 $18,851 [7, 48]
Cervical cancer stage 3 $18,851 [7, 48]
Cervical cancer stage 4 $25,759 [7, 48]
Utilities   
Normal Population 0.94-0.89 (age-specific) [58]
CIN lesion 0.96-0.995 [59, 60]
Cervical cancer 0.73 [59, 60]
Cured cancer 0.94 [61]